Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Matheus M. Lôbo
Observed names:
Lôbo, Matheus M.,
Matheus Lobo,
Matheus Lôbo
Institutions:
Brigham and Women's Hospital,
Harvard University,
AC Camargo Hospital,
Dana-Farber Cancer Institute
Observed institutions:
Brigham and Women's Hospital,
Harvard University,
AC Camargo Hospital,
Dana-Farber Cancer Institute
OpenAlex ID:
A5113046153
Resting-state electroencephalography delta and theta bands as compensatory oscillations in chronic neuropathic pain: a secondary data analysis
2024
·
Sara Pinto Barbosa
, Ygor Nascimento Junqueira
, et al.
·
Brain Network and Modulation
·
13
Survival outcomes in patients with de novo metastatic Merkel cell carcinoma according to site of metastases
2024
·
Karam Khaddour
, Mofei Liu
, et al.
·
Frontiers in Oncology
·
3
PDF
Safety and efficacy of interleukin-6 blockade for immune-related adverse events: A systematic review and meta-analysis.
2024
·
Maysa Vilbert
, Erica C. Koch Hein
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Analysis of neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma using the SWOG S1801 event-free survival definition.
2024
·
Milton Jose De Barros E Silva
, Monique Celeste Tavares
, et al.
·
Journal of Clinical Oncology
·
1
PDF
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.
2023
·
Milton Jose De Barros E Silva
, Monique Celeste Tavares
, et al.
·
Journal of Clinical Oncology
·
1
FDG-PET/CT response and outcome of neoadjuvant immunotherapy for clinical stage III melanoma.
2021
·
Milton Jose De Barros E. Silva
, Caio Dabbous Liz
, et al.
·
Journal of Clinical Oncology
·
1
Editorial: The Critical Role of Surgery for Local Disease Control and Nodal Assessment in Merkel Cell Carcinoma
2026
·
Matheus Lôbo
, Michael E Egger
·
Annals of Surgical Oncology
PDF
Using stage-matched genomic analysis to support molecular similarity of unknown-primary Merkel cell carcinoma and identify ARID1B as a prognostic marker.
2026
·
Furkan Bahar
, Matheus Lobo
, et al.
·
Journal of Clinical Oncology
Cost-saving analysis of neoadjuvant versus adjuvant immunotherapy in clinical stage III melanoma: A real-world Brazilian perspective.
2026
·
Ana Paula Beck da Silva Etges
, Milton Jose De Barros E. Silva
, et al.
·
Journal of Clinical Oncology
High tumor mutational burden and PIK3CA mutations correlate with poor Merkel cell carcinoma–specific survival
2026
·
Matheus Lobo
, Furkan Bahar
, et al.
·
JCI Insight
PDF
NEOSENT: Neoadjuvant anti-PD-1 therapy for patients with high-risk clinical stage II melanoma with a scheduled sentinel lymph node biopsy.
2025
·
Milton Jose De Barros E. Silva
, Matheus Lobo
, et al.
·
Journal of Clinical Oncology
Combined EORTC FDG-PET/CT and RECIST 1.1 response criteria and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.
2024
·
Milton Jose De Barros E Silva
, Monique Celeste Tavares
, et al.
·
Journal of Clinical Oncology
Recurrence Patterns and Clinical Management after a Positive Sentinel Node Biopsy in Melanoma Patients
2023
·
Jacqueline N. de Menezes
, Dante A. S. M. Arra
, et al.
·
Cancer Investigation
Show more works
View as search
Works count:
14
Citation count:
21
H-index:
2
I10-index:
1
Year
Topic
Type
